Application No: NA_00072395
Principal Investigator: Daniel Harrison
For more information please contact Daniel Harrison at 443-287-0400
This research is being conducted to determine if a medicine called AVP-923 (Dextromethorphan/Quinidine) is safe and effective at reducing symptoms of central neuropathic pain due to multiple sclerosis. Neuropathic pain is often experienced as chronic pain in the extremities, and is usually not responsive to standard pain relief medications. AVP-923 is currently FDA-approved for use in patients with pseudobulbar affect, and is taken as an oral medication.
Participants must be between the ages of 18 and 85, experience neuropathic pain, and have a diagnosis of multiple sclerosis. Participants will be randomly assigned to receive either one of 3 doses of the study drug or a matching placebo, which will be taken twice daily as an oral medication for an 85 day study period. The success or failure of pain control will be assessed by self-assessment tools.
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts